National Cancer Institute to Grant Exclusive Patent License for KK-LC-1 T Cell Receptor Cancer Treatment

Summary

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to T-Cure Biosciences, Inc. for the development of a cancer treatment targeting KK-LC-1 expressing human cancer cells.